Onconic Therapeutics to Present at BIO USA... Expanding Global Partnering for Nesuparib

Onconic Therapeutics announced on June 12, 2026, that it will participate in the 'BIO International Convention 2026 (BIO USA 2026),' which will be held in San Diego, USA, from the 22nd to the 25th (local time). The company will conduct a company presentation and hold business meetings during the event.

BIO USA is the world's largest pharmaceutical and biotech industry event, organized by the Biotechnology Innovation Organization. It serves as a leading business partnering platform, bringing together global pharmaceutical companies, biotech firms, investment institutions, and research organizations.

Onconic Therapeutics plans to send its largest-ever delegation to this event, including CEO John Kim, the business development (BD) team, research staff, and executives selected for partnering capabilities. In particular, since the recent disclosure of clinical data on Nesuparib at ASCO 2026, global industry interest has grown significantly, leading to a surge in partnering meeting requests. To fully capitalize on the comprehensive partnering meeting schedule during BIO USA and expand discussions on global commercialization, the company has decided to increase the size of its delegation.

At the event, CEO John Kim will deliver the company presentation in person on the 24th, introducing the company's key pipeline, research and development capabilities, and global commercialization strategies. The presentation will especially highlight the clinical development achievements and global competitiveness of Nesuparib (JPI-547, Nesuparib), a dual-targeted anticancer drug candidate, emphasizing its potential as a next-generation pan-tumor anticancer therapy.

Nesuparib is a first-in-class dual-targeted synthetic lethality anticancer agent that simultaneously targets tankyrase and PARP (a key enzyme involved in the repair of damaged DNA within cells). It is attracting attention as a next-generation anticancer drug that may overcome the limitations of existing PARP-based treatments. Currently, Nesuparib is under phase 2 clinical development for four indications: pancreatic cancer, endometrial cancer, ovarian cancer, and gastric cancer.

Last month, Onconic Therapeutics presented the results of the phase 1b clinical trial of Nesuparib in patients with metastatic pancreatic cancer at the American Society of Clinical Oncology (ASCO) 2026 annual meeting. The study revealed encouraging clinical data, including over 40 months of continued complete response (CR) in target lesions and long-term survival in patients with metastatic pancreatic cancer, drawing significant attention from the industry. Notably, despite most clinical trial participants being metastatic patients, overall survival (OS) exceeded the median overall survival (mOS) of existing standard treatments, demonstrating the potential for extending survival in the hard-to-treat field of metastatic pancreatic cancer.

This is significant in that it proves the metastasis inhibition mechanism and preclinical results of Nesuparib, presented at AACR 2026 last April, are being realized in actual clinical patients. The dual mechanism of Nesuparib is raising expectations for its potential as a pan-tumor therapy.

Onconic Therapeutics has already demonstrated its global commercialization capabilities through the success of Jacuvo, Korea's 37th new drug. Jacuvo has signed out-licensing and supply agreements in 27 countries worldwide. Following its approval in Korea, clinical phase 3 trials in China and India were successfully completed, and regulatory reviews are underway. On June 9, the company submitted a local regulatory application in Mexico, and on June 11, it signed a licensing and supply agreement in Indonesia, the largest market in ASEAN, putting the company on track for entry into Central and South America and Southeast Asia. Leveraging the global commercialization experience and partnership network gained through Jacuvo, the company plans to accelerate the global expansion of Nesuparib.

John Kim, CEO of Onconic Therapeutics, stated, "Since our ASCO presentation, interest in Nesuparib has grown even further, and BIO USA 2026 will serve as a key opportunity to discuss commercialization strategies with global partners based on our R&D achievements. Building on our proven track record in new drug development and commercialization with Jacuvo, we will promote the competitiveness of Nesuparib and actively seek various collaboration opportunities with global big pharma and overseas partners to ensure the success of Nesuparib as a pan-tumor anticancer drug."

This content was produced with the assistance of AI translation services.